<![CDATA[Relapsed/Refractory Multiple Myeloma: Clinical Development and Early Experience With Talquetamab]]>

Summary

Dr. Ajai Chari and Dr. Rahul Banerjee review the clinical development of talquetamab in relapsed/refractory multiple myeloma, focusing on findings from the MonumenTAL-1 study and GPRC5D-directed therapy evolution. This is a routine educational review without new trial results or regulatory decisions.